

08/874,992

-2-

undersigned attorney participating. Reconsideration and further examination of the application are requested.

Also presented as a section of this paper is an Interview Summary, which is a brief account of the interview of Applicant Jonathan S. Stamler and the undersigned attorney Carol A. Eigner with Examiner Celsa on February 13, 2001.

Please amend the application as follows:

In the Claims

Cancel Claims 50, 52, 54, 55, 57 and 58.

2 Add the following claims. }

64. A method for treating a disorder resulting from platelet activation or adherence in an animal or human, comprising administering to the animal or human a composition comprising SNO-I1b[Fe(II)] in a therapeutically effective amount.
65. A method for preventing thrombus formation in an animal or human, comprising administering to the animal or human a composition comprising SNO-Hb[Fe(III)] in a therapeutically effective amount.
66. A method for treating a disorder resulting from platelet activation or adherence in an animal or human, comprising administering to the animal or human a composition comprising polynitrosated hemoglobin in a therapeutically effective amount.
67. A method for treating a disorder resulting from platelet activation or adherence in an animal or human, comprising administering to the animal or human a composition comprising SNO-Hb[Fe(II)] in a therapeutically effective amount.